Jie Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jie Li has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kaifeng Li
Department of Neurology, Shenzhen Hospital of Southern Medical University, Shenzhen, China
2 shared publications - Xiongjun He
Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, China
2 shared publications - Yajie Liu
Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, China
2 shared publications - Baixuan He
Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
1 shared publication - Dehui Huang
Department of Neurology, Chinese PLA General Hospital, Beijing 100853, PR China.
1 shared publication - Dong Pan
Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China (D.P.).
1 shared publication
Latest Publications
- Open Access
Intra-arterial alteplase for acute ischaemic stroke after mechanical thrombectomy (PEARL): rationale and design of a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial
Introduction: Successful reperfusion does not always lead to good neurological outcomes and impaired microcirculation can be one of the underlying causes. Intra-arterial alteplase after mechanical thrombectomy (MT) may improve microcirculation contributing to neurological recovery, but prospective randomised studies are still needed to validate its efficacy and safety. We aim to assess the efficacy and safety of intra-arterial alteplase after MT for acute ischaemic stroke (AIS) with large-vessel occlusion (LVO). Methods and analysis: The Intra-arterial Alteplase for Acute Ischaemic Stroke After Mechanical Thrombectomy (PEARL) study is a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial. We consecutively screen AIS patients with anterior circulation LVO and National Institute of Health Stroke Scale of 6–25, who reach stable expanded Thrombolysis in Cerebral Infarction scores of 2b50-3 on angiography after MT. Eligible participants are 1:1 randomly assigned to the experimental group and the control group. Participants in the experimental group will receive intra-arterial alteplase (0.225 mg/kg and a maximum dose of 20 mg) after MT and standard medical treatment, while those in the control group will receive standard medical treatment alone after the procedure. The primary outcome is the proportion of patients with a 90-day modified Rankin scale of 0–1. A total of 324 participants are required to test the superiority hypothesis with 80% power at a two-tailed significance level of 0.05. Ethics and dissemination: This study has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (SYSKY-2023-390-02) and will be conducted following the Declaration of Helsinki. Ethical approvals have been obtained separately for all centres participating in the study. Study results will be published in peer-reviewed academic journals. Trial registration number: NCT05856851 .
Open AccessIntra-arterial alteplase for acute ischaemic stroke after mechanical thrombectomy (PEARL): rationale and design of a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial
Introduction: Successful reperfusion does not always lead to good neurological outcomes and impaired microcirculation can be one of the underlying causes. Intra-arterial alteplase after mechanical thrombectomy (MT) may improve microcirculation contributing to neurological recovery, but prospective randomised studies are still needed to validate its efficacy and safety. We aim to assess the efficacy and safety of intra-arterial alteplase after MT for acute ischaemic stroke (AIS) with large-vessel occlusion (LVO). Methods and analysis: The Intra-arterial Alteplase for Acute Ischaemic Stroke After Mechanical Thrombectomy (PEARL) study is a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial. We consecutively screen AIS patients with anterior circulation LVO and National Institute of Health Stroke Scale of 6–25, who reach stable expanded Thrombolysis in Cerebral Infarction scores of 2b50-3 on angiography after MT. Eligible participants are 1:1 randomly assigned to the experimental group and the control group. Participants in the experimental group will receive intra-arterial alteplase (0.225 mg/kg and a maximum dose of 20 mg) after MT and standard medical treatment, while those in the control group will receive standard medical treatment alone after the procedure. The primary outcome is the proportion of patients with a 90-day modified Rankin scale of 0–1. A total of 324 participants are required to test the superiority hypothesis with 80% power at a two-tailed significance level of 0.05. Ethics and dissemination: This study has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (SYSKY-2023-390-02) and will be conducted following the Declaration of Helsinki. Ethical approvals have been obtained separately for all centres participating in the study. Study results will be published in peer-reviewed academic journals. Trial registration number: NCT05856851 .
- Open Access
- 1 January 2024
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2024 (1)
Circulating Inflammatory Markers in COVID‐19‐Related Ischemic Stroke: A Multicenter Retrospective Analysis
The novel coronavirus disease 2019 (COVID‐19) causes severe respiratory illness and is involved in ischemic stroke. Aimed to investigate the inflammatory markers and possible prognosis of COVID‐19‐related ischemic stroke in a special outbreak period after lifting of COVID‐19 control measures in China, we conducted a multicenter retrospective analysis in southern China at three centers in Shenzhen. We included patients diagnosed with acute ischemic stroke or transient ischemic attack after infection with COVID‐19 as the COVID‐19‐related ischemic stroke group and those only diagnosed with acute ischemic stroke or transient ischemic attack as the control group. In this study, the proportion of female patients, admission heart rate, and comorbid coronary heart disease and the proportion of cryptogenic stroke were higher, while the history of prior stroke was lower in the COVID‐19‐related ischemic stroke group. The COVID‐19‐related ischemic stroke group also exhibited elevated levels of monocytes, fibrinogen, alanine aminotransferase, direct bilirubin, monocyte‐to‐lymphocyte ratio (MLR), and fibrinogen‐to‐albumin ratio (FAR) but decreased levels of lymphocytes, albumin, and high‐density lipoprotein. However, there were no statistically significant differences in the modified Rankin scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and mortality rate between the two groups at discharge. Our study is the first to show the alteration in inflammatory markers but no difference in discharge prognosis between the non‐COVID‐19 and the COVID‐19‐related ischemic stroke patients, during China’s COVID‐19 relaxation period.
- 1 January 2024
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2024 (1)
Open AccessCirculating Inflammatory Markers in COVID‐19‐Related Ischemic Stroke: A Multicenter Retrospective Analysis
The novel coronavirus disease 2019 (COVID‐19) causes severe respiratory illness and is involved in ischemic stroke. Aimed to investigate the inflammatory markers and possible prognosis of COVID‐19‐related ischemic stroke in a special outbreak period after lifting of COVID‐19 control measures in China, we conducted a multicenter retrospective analysis in southern China at three centers in Shenzhen. We included patients diagnosed with acute ischemic stroke or transient ischemic attack after infection with COVID‐19 as the COVID‐19‐related ischemic stroke group and those only diagnosed with acute ischemic stroke or transient ischemic attack as the control group. In this study, the proportion of female patients, admission heart rate, and comorbid coronary heart disease and the proportion of cryptogenic stroke were higher, while the history of prior stroke was lower in the COVID‐19‐related ischemic stroke group. The COVID‐19‐related ischemic stroke group also exhibited elevated levels of monocytes, fibrinogen, alanine aminotransferase, direct bilirubin, monocyte‐to‐lymphocyte ratio (MLR), and fibrinogen‐to‐albumin ratio (FAR) but decreased levels of lymphocytes, albumin, and high‐density lipoprotein. However, there were no statistically significant differences in the modified Rankin scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and mortality rate between the two groups at discharge. Our study is the first to show the alteration in inflammatory markers but no difference in discharge prognosis between the non‐COVID‐19 and the COVID‐19‐related ischemic stroke patients, during China’s COVID‐19 relaxation period.
- Open Access
- 16 September 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-8
Clinical, neuroimaging, biochemical, and genetic features in six Chinese patients with Adrenomyeloneuropathy
Background: Adrenoleukodystrophy is a rare neurogenetic disease, AMN is the most common adult phenotype, such patients in China have not gotten enough attention. This article aims to study the features of AMN in Chinese patients and expand the gene spectrum of Chinese X-linked adrenoleukodystrophy (X-ALD) patients. Methods: We applied clinical analysis, radiology, plasma levels of very long chain fatty acids (VLCFA) and genetic analysis to test the 6 Chinese AMN patients. Results: All 6 patients are men. Ages of neurological symptom onset are distributed between 21 and 38. Sexual dysfunction occurred in 5 of 6 patients. Three patients had positive family history. Five patients had Addison’s disease. Four patients were diagnosed as pure AMN, while the other two patients were with cerebral involvement. Four patients had abnormalities of nerve conduction studies. There were four patients with central conduction defects in somatosensory evoked potential tests. All 6 patients were found diffuse cord atrophy in spinal MRI. Brain MRI showed abnormal signals in 2 of the 6 tested patients, which indicated the clinical phenotypes. Plasma levels of VLCFA, as well as C24:0/C22:0 and C26:0/C22:0 ratios were elevated in 5 tested patients. Five different ABCD1 mutations were identified in 5 tested patients, one of which was a de novo mutation, and the other four have been reported previously. Conclusion: This research described the clinical, neuroimaging, biochemical, and genetic sides of Chinese AMN patients. A de novo mutation in the ABCD1 gene sequence was identified. Emotional trauma may trigger or aggravate the development of cerebral demyelination in AMN patients. Regular evaluation of brain MRI is important for AMN patients, especially for ‘pure AMN’ patients. When encountering patients with ‘myeloneuropathy-only’, neurologists should not ignore the tests of VLCFA or/and the ABCD1 gene.
- 16 September 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 1-8
Open AccessClinical, neuroimaging, biochemical, and genetic features in six Chinese patients with Adrenomyeloneuropathy
Background: Adrenoleukodystrophy is a rare neurogenetic disease, AMN is the most common adult phenotype, such patients in China have not gotten enough attention. This article aims to study the features of AMN in Chinese patients and expand the gene spectrum of Chinese X-linked adrenoleukodystrophy (X-ALD) patients. Methods: We applied clinical analysis, radiology, plasma levels of very long chain fatty acids (VLCFA) and genetic analysis to test the 6 Chinese AMN patients. Results: All 6 patients are men. Ages of neurological symptom onset are distributed between 21 and 38. Sexual dysfunction occurred in 5 of 6 patients. Three patients had positive family history. Five patients had Addison’s disease. Four patients were diagnosed as pure AMN, while the other two patients were with cerebral involvement. Four patients had abnormalities of nerve conduction studies. There were four patients with central conduction defects in somatosensory evoked potential tests. All 6 patients were found diffuse cord atrophy in spinal MRI. Brain MRI showed abnormal signals in 2 of the 6 tested patients, which indicated the clinical phenotypes. Plasma levels of VLCFA, as well as C24:0/C22:0 and C26:0/C22:0 ratios were elevated in 5 tested patients. Five different ABCD1 mutations were identified in 5 tested patients, one of which was a de novo mutation, and the other four have been reported previously. Conclusion: This research described the clinical, neuroimaging, biochemical, and genetic sides of Chinese AMN patients. A de novo mutation in the ABCD1 gene sequence was identified. Emotional trauma may trigger or aggravate the development of cerebral demyelination in AMN patients. Regular evaluation of brain MRI is important for AMN patients, especially for ‘pure AMN’ patients. When encountering patients with ‘myeloneuropathy-only’, neurologists should not ignore the tests of VLCFA or/and the ABCD1 gene.